Testosterone Propionate Boosts Aggression in Hypogonadal Men: 5-Year Longitudinal Study
Reading Time: < 1 minuteIntroduction Testosterone propionate (TP), a short-acting ester of testosterone, has been a cornerstone in androgen replacement therapy (ART) for hypogonadal American males, particularly those experiencing age-related declines in endogenous testosterone production. With over 4 million U.S. men diagnosed with hypogonadism annually, per Centers for Disease Control and Prevention (CDC) data, TP's intramuscular administration offers rapid pharmacokinetics, achieving peak serum levels... Read more »
